| Similar Articles |
|---|
 |
The Motley Fool
August 28, 2009
Brian Orelli |
Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics.   |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
June 29, 2007
Brian Lawler |
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
October 20, 2011
Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
October 26, 2004
Charly Travers |
Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
July 14, 2009
Brian Orelli |
Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
November 13, 2009
Brian Orelli |
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
Bio-IT World
February 10, 2003
Malorye Branca |
The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success. |
The Motley Fool
June 5, 2008
Brian Lawler |
Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
March 22, 2005
Charly Travers |
Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials. |
The Motley Fool
June 29, 2010
Brian Orelli |
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
December 18, 2009
Brian Orelli |
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
November 16, 2004
Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. |
The Motley Fool
June 14, 2011
Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool
March 30, 2004
David Nierengarten |
Jumping Biotechs A cancer research conference drives smaller biotechs higher. |
The Motley Fool
September 24, 2010
Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue. |
The Motley Fool
February 27, 2009
Brian Orelli |
Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas. |
The Motley Fool
January 15, 2012
Brian Orelli |
3 Lessons From the J.P. Morgan Health-Care Confab After 30 years, the conference still offers useful takeaways. This years: Some biotechs never die... In the United States, more people die from flu each year than die from HIV AIDS... Drug launches are back (maybe)... |
Chemistry World
October 21, 2011
Sarah Houlton |
Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns. |
Pharmaceutical Executive
August 1, 2006 |
Introduction: Pharm Exec at 25 A pharmaceuticals magazine celebrates its 25th anniversary. |
